Last reviewed · How we verify

Hiberix™ Vaccine — Competitive Intelligence Brief

Hiberix™ Vaccine (Hiberix™ Vaccine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Conjugate vaccine. Area: Immunology / Infectious Disease.

phase 3 Conjugate vaccine Haemophilus influenzae type b polysaccharide capsule (PRP) Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

Hiberix™ Vaccine (Hiberix™ Vaccine) — LG Life Sciences. Hiberix is a conjugate vaccine that stimulates the immune system to produce antibodies against Haemophilus influenzae type b (Hib) by linking the bacterial polysaccharide capsule to a protein carrier.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Hiberix™ Vaccine TARGET Hiberix™ Vaccine LG Life Sciences phase 3 Conjugate vaccine Haemophilus influenzae type b polysaccharide capsule (PRP)
Prevnar 20 pneumococcal 20-valent conjugate vaccine (PCV20) Pfizer Inc. marketed Pneumococcal conjugate vaccine Streptococcus pneumoniae capsular polysaccharides (20 serotypes) 2021-06-08
NeisVac-C® NeisVac-C® Merck Sharp & Dohme LLC marketed Meningococcal conjugate vaccine Neisseria meningitidis serogroup C polysaccharide capsule
4CMenb 4CMenb CHU de Quebec-Universite Laval marketed Conjugate vaccine Neisseria meningitidis serogroup B polysaccharide capsule
Prevenar and Meningitec Prevenar and Meningitec Wyeth is now a wholly owned subsidiary of Pfizer marketed Conjugate vaccine Streptococcus pneumoniae polysaccharide capsule (Prevenar); Neisseria meningitidis serogroup C polysaccharide capsule (Meningitec)
MCV4 MCV4 CanSino Biologics Inc. marketed Meningococcal conjugate vaccine Neisseria meningitidis serogroups A, C, W, Y polysaccharide capsules
MenACWY MenACWY LimmaTech Biologics AG marketed Conjugate vaccine Neisseria meningitidis serogroups A, C, W, Y polysaccharide capsules

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

Sponsor landscape (Conjugate vaccine class)

  1. GlaxoSmithKline · 26 drugs in this class
  2. Sanofi Pasteur, a Sanofi Company · 6 drugs in this class
  3. CanSino Biologics Inc. · 3 drugs in this class
  4. MCM Vaccines B.V. · 3 drugs in this class
  5. Beijing Minhai Biotechnology Co., Ltd · 3 drugs in this class
  6. Wyeth is now a wholly owned subsidiary of Pfizer · 2 drugs in this class
  7. PT Bio Farma · 2 drugs in this class
  8. LG Life Sciences · 2 drugs in this class
  9. Walvax Biotechnology Co., Ltd. · 2 drugs in this class
  10. Heinrich-Heine University, Duesseldorf · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Hiberix™ Vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/hiberix-vaccine. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: